Huang F - Search Results

1

A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors.

Weekes C, Lockhart AC, Lee JJ, Sturm I, Cleton A, Huang F, Lenz HJ. Weekes C, et al. Among authors: huang f. Int J Cancer. 2019 Nov 1;145(9):2450-2458. doi: 10.1002/ijc.32317. Epub 2019 Jun 14. Int J Cancer. 2019. PMID: 30958892 Free PMC article. Clinical Trial.

2

²²⁷Th-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I Study.

Lindén O, Bates AT, Cunningham D, Hindorf C, Larsson E, Cleton A, Pinkert J, Huang F, Bladt F, Hennekes H, Oedegaardstuen LI, Sturm I, McNamara C. Lindén O, et al. Among authors: huang f. Cancer Biother Radiopharm. 2021 Oct;36(8):672-681. doi: 10.1089/cbr.2020.4653. Epub 2021 Apr 21. Cancer Biother Radiopharm. 2021. PMID: 33887152 Clinical Trial.

3

Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer.

Wong SK, Chu QSC, Spratlin JL, Sangha R, McEwan AJB, Morrish DW, Arndt D, Sergenson G, Cleton A, Huang F, Sawyer MB. Wong SK, et al. Among authors: huang f. Case Rep Oncol. 2019 Oct 16;12(3):791-795. doi: 10.1159/000503419. eCollection 2019 Sep-Dec. Case Rep Oncol. 2019. PMID: 31762750 Free PMC article.

4

Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors.

Marmé F, Gomez-Roca C, Graudenz K, Huang F, Lettieri J, Peña C, Trnkova ZJ, Eucker J. Marmé F, et al. Among authors: huang f. Cancer Chemother Pharmacol. 2018 Apr;81(4):727-737. doi: 10.1007/s00280-018-3540-9. Epub 2018 Feb 21. Cancer Chemother Pharmacol. 2018. PMID: 29468456 Clinical Trial.

5

No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects.

Huang F, Ajavon A, Huang E, Lettieri J, Liu R, Peña C, Berse M. Huang F, et al. Among authors: huang e. Thyroid. 2017 Sep;27(9):1118-1127. doi: 10.1089/thy.2017.0085. Epub 2017 Aug 29. Thyroid. 2017. PMID: 28741453 Free PMC article. Clinical Trial.

6

A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma.

Liu W, Ping L, Xie Y, Sun Y, Du T, Niu Y, Cisternas G, Huang F, Garcia-Vargas J, Childs BH, Mehra A, Reschke S, Wang X, Song Y, Zhu J. Liu W, et al. Among authors: huang f. Cancer Chemother Pharmacol. 2022 Jun;89(6):825-831. doi: 10.1007/s00280-022-04417-3. Epub 2022 Mar 23. Cancer Chemother Pharmacol. 2022. PMID: 35322287 Clinical Trial.

7

Exposure-Response Modeling and Simulation of Progression-Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer.

Grevel J, Jentsch G, Austin R, Prins NH, Lettieri J, Mitchell D, Huang F, Brose MS, Schlumberger M, Meinhardt G, Peña CEA, Ploeger BA. Grevel J, et al. Among authors: huang f. Clin Transl Sci. 2019 Sep;12(5):459-469. doi: 10.1111/cts.12634. Epub 2019 Apr 12. Clin Transl Sci. 2019. PMID: 30920122 Free PMC article. Clinical Trial.

8

Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment.

Zurth C, Nykänen P, Wilkinson G, Taavitsainen P, Vuorela A, Huang F, Reschke S, Koskinen M. Zurth C, et al. Among authors: huang f. Clin Pharmacokinet. 2022 Apr;61(4):565-575. doi: 10.1007/s40262-021-01078-y. Epub 2021 Dec 6. Clin Pharmacokinet. 2022. PMID: 34866168 Free PMC article.

9

Molecular Mechanism of Ginsenoside Rg3 Alleviation in Osteoporosis via Modulation of KPNA2 and the NF-κB Signalling Pathway.

Zhang X, Huang F, Liu J, Zhou Z, Yuan S, Jiang H. Zhang X, et al. Among authors: huang f. Clin Exp Pharmacol Physiol. 2025 Mar;52(3):e70019. doi: 10.1111/1440-1681.70019. Clin Exp Pharmacol Physiol. 2025. PMID: 39821958

10

The microbial mechanism of maize residue decomposition under different temperature and moisture regimes in a Solonchak.

Huang F, Zhang W, Xue L, Razavi B, Zamanian K, Zhao X. Huang F, et al. Sci Rep. 2025 Jan 17;15(1):2215. doi: 10.1038/s41598-024-81292-3. Sci Rep. 2025. PMID: 39820291

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11,411 results

Search Page

Filters